Project Details
Description
The primary goal of the project is to determine the combined response of urothelial carcinoma
to Veliparib and anti-PD-1/PD-L1 therapy.
| Status | Finished |
|---|---|
| Effective start/end date | 9/29/17 → 9/29/19 |
Funding
- AbbVie Inc. (Agmt 9/29/17)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.